Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Turnstone Biologics Corp. Common Stock (TSBX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: TSBX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1
1 Year Target Price $1
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -32.92% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.16M USD | Price to earnings Ratio - | 1Y Target Price 1 |
Price to earnings Ratio - | 1Y Target Price 1 | ||
Volume (30-day avg) 1 | Beta - | 52 Weeks Range 0.29 - 2.69 | Updated Date 06/30/2025 |
52 Weeks Range 0.29 - 2.69 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.73 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -63.31% | Return on Equity (TTM) -126.03% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -12851929 | Price to Sales(TTM) 2.13 |
Enterprise Value -12851929 | Price to Sales(TTM) 2.13 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.8 | Shares Outstanding 23140300 | Shares Floating 14104506 |
Shares Outstanding 23140300 | Shares Floating 14104506 | ||
Percent Insiders 7.7 | Percent Institutions 52.82 |
Analyst Ratings
Rating 1 | Target Price 1 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Turnstone Biologics Corp. Common Stock
Company Overview
History and Background
Turnstone Biologics Corp. is a clinical-stage biotechnology company focused on developing innovative cancer immunotherapies. Founded in 2015, the company aims to harness the power of the immune system to fight cancer. It went public via IPO in 2023.
Core Business Areas
- Tumor-Infiltrating Lymphocyte (TIL) Therapy: Developing personalized TIL therapies for solid tumors, aiming to enhance the body's natural ability to fight cancer.
- Oncolytic Virus Immunotherapy: Creating novel oncolytic viruses designed to selectively infect and destroy cancer cells, while also stimulating an immune response.
Leadership and Structure
The leadership team consists of experienced executives in biotechnology and oncology. The organizational structure is typical of a clinical-stage biotech company, with departments focused on research, development, clinical trials, and business operations.
Top Products and Market Share
Key Offerings
- TIL Therapy (currently in clinical trials): Turnstone's lead TIL therapy is being evaluated in clinical trials for multiple solid tumor types. Market share is currently 0% as no products are approved. Competitors include Iovance Biotherapeutics (IOVA) and other companies developing TIL therapies.
- Oncolytic Virus Immunotherapy (currently in preclinical/clinical trials): Turnstone's oncolytic virus platform is generating several product candidates for different cancer types. Market share is currently 0% as no products are approved. Competitors include Replimune Group (REPL) and BioNTech (BNTX) in the oncolytic virus space.
Market Dynamics
Industry Overview
The cancer immunotherapy market is rapidly growing, driven by advances in understanding the immune system and the development of new therapeutic approaches. Significant investment and competition exist within the space.
Positioning
Turnstone Biologics is positioned as an innovator in TIL therapy and oncolytic virus immunotherapy, focusing on solid tumors. Their competitive advantage lies in their platform technologies and the potential for personalized therapies.
Total Addressable Market (TAM)
The global cancer immunotherapy market is projected to reach hundreds of billions of dollars. Turnstone is targeting specific solid tumor types, positioning them to capture a portion of this market as their therapies progress through clinical trials and potential regulatory approvals.
Upturn SWOT Analysis
Strengths
- Innovative platform technologies (TIL and oncolytic viruses)
- Experienced leadership team
- Strong intellectual property portfolio
- Focus on difficult-to-treat solid tumors
- Personalized therapy approach
Weaknesses
- Early-stage clinical development (high risk)
- Limited financial resources compared to larger companies
- Reliance on successful clinical trial outcomes
- Manufacturing complexities of personalized therapies
Opportunities
- Positive clinical trial results leading to regulatory approvals
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
- Advancements in manufacturing technologies
- Increasing demand for personalized cancer therapies
Threats
- Clinical trial failures
- Competition from other immunotherapy companies
- Regulatory hurdles
- Patent challenges
- Difficulty in scaling up manufacturing
Competitors and Market Share
Key Competitors
- IOVA
- REPL
- BNTX
- ZIOP
Competitive Landscape
Turnstone faces competition from established immunotherapy companies and other emerging players in the TIL and oncolytic virus space. Their advantage is its novel technologies and personalized approach, but they need to demonstrate clinical efficacy and navigate regulatory challenges.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by advancement of the pipeline. Prior to going public, growth was fueled by venture capital.
Future Projections: Future growth is dependent on the success of clinical trials, regulatory approvals, and potential partnerships. Analyst projections are based on the market potential of their pipeline and its efficacy.
Recent Initiatives: Recent strategic initiatives include advancing clinical trials for lead candidates and expanding their platform technologies.
Summary
Turnstone Biologics is a clinical-stage company developing innovative cancer immunotherapies with a focus on TIL and oncolytic virus platforms. The company's success hinges on positive clinical trial results and regulatory approvals. They operate in a competitive market but have novel approaches that address unmet needs. Financial risks are inherent in this early stage of development, and cash management is critical for long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual research and consultation with a qualified financial advisor. Market share data is based on current pipeline positioning and not current revenues as they have none.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Turnstone Biologics Corp. Common Stock
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2023-07-21 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://turnstonebio.com |
Full time employees 8 | Website https://turnstonebio.com | ||
Turnstone Biologics Corp. operates as a biotechnology company. The company was founded in 2014 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.